Alnuctamab

Generic Name
Alnuctamab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2296827-07-9
Unique Ingredient Identifier
7OSV6M6T4D
Associated Conditions
-
Associated Therapies
-

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted Date
2024-01-31
Last Posted Date
2024-05-31
Lead Sponsor
Celgene
Registration Number
NCT06232707
Locations
🇺🇸

Local Institution - 0088, Los Angeles, California, United States

🇺🇸

Local Institution - 0324, Baltimore, Maryland, United States

🇦🇺

Local Institution - 0022, Waratah, New South Wales, Australia

and more 167 locations

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2023-12-11
Last Posted Date
2024-10-21
Lead Sponsor
Celgene
Target Recruit Count
156
Registration Number
NCT06163898
Locations
🇺🇸

Local Institution - 0035, New Haven, Connecticut, United States

🇺🇸

Local Institution - 0018, New York, New York, United States

🇺🇸

Local Institution - 0033, Birmingham, Alabama, United States

and more 3 locations

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2023-11-08
Last Posted Date
2024-12-20
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
111
Registration Number
NCT06121843
Locations
🇺🇸

University Of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Local Institution - 0002, Phoenix, Arizona, United States

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath